Patent application number | Description | Published |
20110145154 | Policy Development Criticality And Complexity Ratings - Methods, computer readable media, and apparatuses for policy development and management are presented. One or more policy needs may be identified, and a criticality rating and a complexity rating may be determined for each policy need. The criticality rating and the complexity rating may be based on one or more weighted criticality and complexity factors. The criticality rating may affect prioritization of policy development, and the complexity rating may affect an estimate of time required for policy development. Subsequently, a report may be generated. | 06-16-2011 |
20110145884 | Policy Needs Assessment - Methods, computer readable media, and apparatuses for policy development and management are presented. One or more policy needs may be identified, and a score for each policy need may be determined The score for each policy need may be determined based on audit issue closure date information, legal compliance information, and regulatory impact information. Based on the determined scores, development of one or more policy needs may be prioritized. | 06-16-2011 |
20110145885 | Policy Adherence And Compliance Model - Methods, computer readable media, and apparatuses for policy development and management are presented. Input corresponding to an implemented policy may be received. An adherence rating for the implemented policy may be determined based on a measured level of compliance with at least one guiding principle. An effectiveness rating for the implemented policy may be determined based on a determined level of responsiveness. Subsequently, a report may be generated. | 06-16-2011 |
Patent application number | Description | Published |
20110190572 | Methods and Compositions for Vein Harvest and Autografting - The leading cause of graft failure is the subsequent development of intimal hyperplasia, which represents a response to injury that is thought to involve smooth muscle proliferation, migration, phenotypic modulation, and extracellular matrix (ECM) deposition. Surgical techniques typically employed for vein harvest—stretching the vein, placing the vein in low pH, solutions, and the use of toxic surgical skin markers—are shown here to cause injury. The invention therefore provides for non-toxic surgical markers than also protect against stretch-induced loss of functional viability, along with other additives. Devices and compositions for reducing physical stress or protecting from the effects flowing therefrom, also are provided. | 08-04-2011 |
20140220547 | Methods and Compositions for Vein Harvest and Autografting - The leading cause of graft failure is the subsequent development of intimal hyperplasia, which represents a response to injury that is thought to involve smooth muscle proliferation, migration, phenotypic modulation, and extracellular matrix (ECM) deposition. Surgical techniques typically employed for vein harvest—stretching the vein, placing the vein in low pH, solutions, and the use of toxic surgical skin markers—are shown here to cause injury. The invention therefore provides for non-toxic surgical markers than also protect against stretch-induced loss of functional viability, along with other additives. Devices and compositions for reducing physical stress or protecting from the effects flowing therefrom, also are provided. | 08-07-2014 |
Patent application number | Description | Published |
20080293738 | Formulation of Quinolinones - A pharmaceutical formulation, comprising: a compound of formula (I), a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof and at least one ingredient selected from the group consisting of (i) cellulose; (ii) silicon dioxide; (iii) magnesium stearate; and (iv) an ingredient selected from crospovidone, starch, or lactose. | 11-27-2008 |
20090181979 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES - A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R | 07-16-2009 |
20110178097 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-Q- UINOLIN-2-ONE LACTIC ACID SALTS - The present invention relates to non-hydrate crystalline forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts. | 07-21-2011 |
20120208825 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-Q- UINOLIN-2-ONE LACTIC ACID SALTS - The present invention relates to non-hydrate crystalline forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts. | 08-16-2012 |
20120276200 | FORMULATIONS OF QUINOLINONES - A pharmaceutical formulation, comprising: a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof, | 11-01-2012 |
20120277434 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS - A method of synthesizing a substituted or unsubstituted 4-amino-3-benzimidazolyl quinolinone compound includes reacting a first compound having the formula I with a second compound having the formula II in a suitable solvent in the presence of a sodium or potassium salt of a base. The first compound and the second compound have the following structures where the variables have the values described herein: | 11-01-2012 |
20130018058 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES - A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R | 01-17-2013 |
20130338171 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties - A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R | 12-19-2013 |
20140303182 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES - A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R | 10-09-2014 |
Patent application number | Description | Published |
20110237643 | Identification of a Novel repressor on IFN-lambda promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-lambda gene activity - The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases. | 09-29-2011 |
20120058081 | Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-λ | 03-08-2012 |
20120171704 | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor - A naturally-occurring soluble truncated IL-23Rα protein (i.e., Δ9 IL-23Rα) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (ELISA) and test kit for the serological detection of the soluble truncated form of IL-23Rα protein. More particularly, antibody-sandwich ELISA method and kits for Δ9 IL-23Rα as an antigen were developed to detect Δ9 IL-23Rα levels in biological samples from a mammal and a human patient and are used as a diagnostic index. The present disclosed ELISA has utility as a diagnostic tool to detect Crohn's disease in patients using EDTA-plasma. | 07-05-2012 |
20130338211 | NOVEL REPRESSOR ON IFN-LAMBDA PROMOTER AND SIRNA AGAINST ZEB1 AND BLIMP-1 TO INCREASE IFN-LAMBDA GENE ACTIVITY - The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases. | 12-19-2013 |
20140057960 | NOVEL REPRESSOR ON IFN-LAMBDA PROMOTER AND SIRNA AGAINST ZEB1 AND BLIMP-1 TO INCREASE IFN-LAMBDA GENE ACTIVITY - The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases. | 02-27-2014 |
20140272994 | METHODS AND REAGENTS THAT SPECIFICALLY DETECT, DISTINGUISH AND QUANTIFY IFN-LAMBDA2 mRNA FROM IFN-LAMBDA3 mRNA IN HUMANS - The present invention provides a method of specifically detecting IFN-λ2 mRNA or IFN-λ3 mRNA. There is provided a qRT-PCR method specifically detecting, discriminating and quantifying IFN-λ2 and IFN-λ3 mRNA in a biological sample obtained from a human. There is provided qRT-PCR methods and primers and probes that specifically detect IFN-λ2 mRNA but not IFN-λ3 mRNA and vice versa in humans in order to detect, quantify and discriminate IFN-λ2 mRNA and IFN-λ3 mRNA. | 09-18-2014 |
20140350072 | NOVEL REPRESSOR ON IFN-LAMBDA PROMOTER AND SIRNA AGAINST ZEB1 AND BLIMP-1 TO INCREASE IFN-LAMBDA GENE ACTIVITY - The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases. | 11-27-2014 |
Patent application number | Description | Published |
20150202456 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 07-23-2015 |
20150217129 | SYSTEM AND METHOD FOR THERAPEUTIC MANAGEMENT OF OCULAR HYPERTENSION - One embodiment is directed to a method for treating hypertension within the eye of a patient, comprising: delivering an effective amount of polynucleotide comprising an exogenous receptor genetic material which is expressed in a targeted tissue structure of the eye, wherein the targeted tissue structure has been genetically modified to have light sensitive protein; waiting for a period of time to ensure that sufficient portions of the targeted tissue structure of the eye will express the desired light sensitive protein; and causing controlled mechanical changes to the permeability of the eye by directing light to the targeted tissue structure through a light deliver element optically intercoupled between a light source and the targeted tissue structure of the eye. | 08-06-2015 |
20150217133 | SYSTEM AND METHOD FOR THERAPEUTIC MANAGEMENT OF OCULAR HYPERTENSION - One embodiment is directed to a system for treating hypertension within the eye of a patient, comprising a light delivery element optically intercoupled between a light source and a targeted tissue structure of the eye; wherein the targeted tissue structure has been genetically modified to have light sensitive protein; and wherein exposure of the genetically modified targeted tissue structure to radiation delivered through the light delivery element modulates the contractility of the genetically modified targeted tissue structure to reduce an intraocular pressure within the eye. | 08-06-2015 |
20160038756 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 02-11-2016 |
20160038757 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 02-11-2016 |
20160038758 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 02-11-2016 |
20160038759 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 02-11-2016 |
20160051828 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 02-25-2016 |
20160051830 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 02-25-2016 |
20160051838 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 02-25-2016 |
20160059030 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 03-03-2016 |
20160082279 | SYSTEM AND METHOD FOR OPTOGENETIC THERAPY - Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells. | 03-24-2016 |
Patent application number | Description | Published |
20100236083 | SUNDIAL - Disclosed are embodiments of a sundial. Various embodiments of the sundial disclosed herein may be used to determine the time of day based on the position of the sun. The sundial may utilize a curved reflector to reflect the image of the sun onto a dial-face. The curved reflector may be disposed, at least in part, behind the dial-face. A portion of the curved reflector behind the dial-face may be used to reflect an image of the sun onto a back surface of the dial-face. The reflected image of the sun received on the back of the dial-face may, in some embodiments, be visible on the front surface of the dial-face. The dial-face may have a plurality of time markings positioned thereon. The position of the image of the sun on the dial-face may be compared to the plurality of time markings to determine at least an approximation of the time of day. | 09-23-2010 |
20110225835 | SUNDIAL - Disclosed are embodiments of a sundial. Various embodiments of the sundial disclosed herein may be used to determine the time of day based on the position of the sun. The sundial may utilize a curved reflector to reflect the image of the sun onto a dial-face. The curved reflector may be disposed, at least in part, behind the dial-face. A portion of the curved reflector behind the dial-face may be used to reflect an image of the sun onto a back surface of the dial-face. The reflected image of the sun received on the back of the dial-face may, in some embodiments, be visible on the front surface of the dial-face. The dial-face may have a plurality of time markings positioned thereon. The position of the image of the sun on the dial-face may be compared to the plurality of time markings to determine at least an approximation of the time of day. | 09-22-2011 |
20120151784 | SUNDIAL - Various embodiments of the sundials disclosed herein may be used to determine the time of day based on the position of the sun. The sundial may utilize a curved reflector to reflect the image of the sun onto a dial-face. The curved reflector may be disposed, at least in part, behind the dial-face. A portion of the curved reflector behind the dial-face may be used to reflect an image of the sun onto a back surface of the dial-face. The reflected image of the sun received on the back of the dial-face may, in some embodiments, be visible on the front surface of the dial-face. The dial-face may have a plurality of time markings positioned thereon. The position of the image of the sun on the dial-face may be compared to the plurality of time markings to determine at least an approximation of the time of day. | 06-21-2012 |
20130199050 | SUNDIAL - Embodiments of a sundial. Various embodiments of the sundial disclosed herein may be used to determine the time of day based on the position of the sun. The sundial may comprise an at least substantially spherical curved reflector that may be at least partially transparent and at least partially reflective such that light from the sun can pass through a surface of the reflector and be reflected off of an internal surface of the reflector to reflect an image of the sun from the internal surface. The sundial may further comprise a dial face for viewing of a reflected image of the sun to provide at least an approximate indication of the time based on the position of the reflected image of the sun on the dial face. | 08-08-2013 |
Patent application number | Description | Published |
20090183871 | MICROFLUIDIC SEPARATOR - The present invention provides methods and apparatus for separating and/or analyzing fluids of interest. According to principles of the present invention, fluid analysis is accomplished with microfluidic devices and may be reported in real-time or near real-time in a subterranean environment. In addition or alternative to oilfield applications, the principles of the present invention contemplate separation in a laboratory or other environment for biological sample separation and analytical chemistry applications. The present invention is capable of separating liquid-liquid mixtures or emulsions in a microfluidic device without fouling. | 07-23-2009 |
20100012586 | METHODS AND DEVICES FOR MINIMIZING MEMBRANE FOULING FOR MICROFLUIDIC SEPARATORS - A fluid separation method for performing fluid analysis of an unfiltered fluid. The fluid separation method includes providing a structure with a fluid analyzer and a power supply. Using a substrate for receiving a fluid flow stream of a multiphase mixture through a fluid sample inlet, wherein the substrate interconnects with the structure. Providing a membrane disposed across the fluid sample inlet for separating a fluid of interest from the multiphase mixture, wherein the fluid flow stream of the multiphase mixture has a shear rate that prevents a fouling of the membrane. Finally, the fluid separation method includes the substrate having fabricated channels, such that the fabricated channels are arranged substantially tangent to the fluid stream downstream of the porous membrane. | 01-21-2010 |
20110011157 | GAS CHROMATOGRAPH COLUMN WITH CARBON NANOTUBE-BEARING CHANNEL - A carbon nanostructured micro-fabricated gas chromatography column which is particularly well-suited to the surface well-site and/or the downhole analysis of natural gas in oilfield or gasfield applications (but which may also be used in non-oilfield or non-gasfield situations) is described. This micro-fabricated column integrates a micro-structured substrate such as a silicon substrate with carbon nanotubes as an active nanostructured material in a micro-channel. Benefits of the present invention include enhanced separation of alkanes and isomers, particularly below hexane (i.e., below C | 01-20-2011 |
20130170592 | DEVICE AND METHOD FOR ION GENERATION - Illustrative embodiments of the present invention are directed to devices and methods for ion generation. One such device includes a substrate. The substrate is disposed within a housing that is configured to contain a gas. The substrate includes an interior surface that at least partially defines an interior volume. The substrate also includes a number of channels with walls. Nano-tips are disposed on the walls of the channels. | 07-04-2013 |
Patent application number | Description | Published |
20140023341 | Annotating General Objects in Video - A method for annotating general objects contained in video content is provided. The method sends video data to a client device and receives a first annotation from the client device defining a boundary around a portion of a first frame of the video data. Then, the first annotation is tracked through multiple frames of the video content. Other annotations determined to be associated with annotation that match the first annotation within a threshold are determined where the other annotations are received from other client devices and located in the first frame or other frames from the first frame. The method combines the other annotations and the first annotation into an object track and associates a tag with the object track. The tag is input by at least one of the client devices. | 01-23-2014 |
20140040019 | PREDICTIVE VIDEO ADVERTISING EFFECTIVENESS ANALYSIS - Effectiveness of video content is predicted using an automated or semi-automated analysis process operating on a computer. Video content is analyzed using image and audio data processing to assign a collection of attributes to a video ad. The collection of attributes is correlated to a historical effectiveness (e.g., click-thru rate) of past video ads in the same or similar attribute space to obtain predicted ad effectiveness. Differences between the collection of attributes and historical attribute spaces of greater effectiveness may also be determined and reported in the form of suggestions for improving the effectiveness of the ad. | 02-06-2014 |
20140132833 | Combining Multiple Screens from Multiple Devices in Video Playback - In one embodiment, a method determines multiple screens of multiple mobile computing devices should be combined in playback of a video. A first mobile computing device receives the video and determines device characteristics based on a positioning of the first mobile computing device in relation to a second mobile computing device. Playback characteristics are determined based on the device characteristics. Then, the first mobile computing device renders a first portion of the video on a first screen based on the playback characteristics where a second portion of the video is rendered on a second screen of the second mobile computing device. | 05-15-2014 |
20150046935 | Guaranteed Ad Targeting with Stable Precision - In one embodiment, a method trains a predictive model configured to predict a probability that advertisement (ad) impressions belong to a segment that is being targeted where the ad impressions are provided during sending of videos to users. A first threshold is determined in which the probability predicted from the predictive model is compared to determine whether ad impressions belong to the segment. A distribution probability used in the training of the predictive model is determined. The distribution probability is determined based on a characteristic for ad impressions on a site. Then, a changed distribution probability for the site is determined. The method further determines a second threshold in which the probability predicted from the predictive model is compared to determine whether ad impressions belong to the segment. | 02-12-2015 |
20150058120 | Multiple Precision Ad Targeting - In one embodiment, a method determines advertisement (ad) impressions previously determined for a site and respective predicted probabilities determined for the ad impressions. A mapping table is generated mapping predicted probabilities to respective precisions using seed data associated with the ad impressions. The method generates optimal options for using the first level and the second level for the segment using the mapping table. The optimal options include a first precision for the first level, a second precision for the second level, and a ratio of ad inventories allocated to the first level and the second level. Then the method selects one of the optimal options. The selected one of the optimal options includes parameters including a first threshold for the first level, a second threshold for the second level, and the ratio that are used to test whether a predicted probability for an ad impression is targeted to the first level or the second level. | 02-26-2015 |